Prostate Cancer – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of prostate cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.

Clarivate Epidemiology’s prostate cancer forecast will answer the following questions:

  • Of all people diagnosed with prostate cancer, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of prostate cancer over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 41 prostate cancer patient populations, as follows:

  • Diagnosed incident cases – N0M0 low risk
  • Diagnosed incident cases – N0M0 intermediate risk
  • Diagnosed incident cases – N0M0 high risk
  • Diagnosed incident cases – N1M0
  • Diagnosed incident cases – NxM1
  • Newly diagnosed low/intermediate risk (hormone-sensitive) drug-treated
  • Newly diagnosed high risk/N1M0 (hormone-sensitive) drug-treated
  • Newly diagnosed metastatic (hormone-sensitive) non-drug-treated
  • Biochemically recurrent (hormone-sensitive) non-drug-treated
  • Diagnosed drug-treatable prevalent cases
  • Diagnosed 1st-line metastatic (CR+HS) drug-treatable populations
  • Non-metastatic CRPC non-drug-treated
  • Diagnosed third/fourth-line mCRPC non-drug-treated
  • … and many more (details available on request).

Note: coverage may vary by country.

launch Related Market Assessment Reports